{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:27Z","timestamp":1787027007863,"version":"build-2736575974"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX09304029-005-02"],"award-info":[{"award-number":["2017ZX09304029-005-02"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The global prevalence of allergic diseases has led to a negative and extensive impact on the health and lives of a large population of children. This study investigates the efficacy, acceptability, and safety of cetirizine (CTZ) for treating allergic diseases in children and provides evidence-based assertions for decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Embase, the Cochrane Library, World Health Organization International Clinical Trials Registry Platform,\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , and the European Union Clinical Trials Register were systematically searched from inception to April 21, 2022. Randomized controlled trials (RCTs) or quasi-RCTs of children with allergic diseases receiving CTZ compared with those receiving placebo or other drugs were included without language limitations. Two investigators independently identified articles, extracted data, conducted meta-analyses, assessed the Cochrane risk of bias of individual studies, and evaluated the evidence certainty using the Grading of Recommendations Assessment, Development, and Evaluation approach; any discrepancies were resolved by consulting with a third investigator. Primary outcomes included scales that evaluated the recovery of allergic conditions in AR, such as the total symptom score (TSS). Secondary outcomes included laboratory test changes, safety (adverse events, AEs), and quality of life (QOL). Data were pooled using the Cochrane Review Manager 5.4, and a fixed-effects model was used if heterogeneity was evaluated as low (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      &amp;lt; 50%); otherwise, a random-effects model was adopted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 22 studies (5,867 patients) were ultimately included [eight with perennial AR, six with seasonal AR, four with atopic dermatitis (AD), and four with other allergic diseases], most of which had a low or unclear risk of bias. Moderate certainty evidence showed that CTZ was found to benefit allergic symptom control [mean difference (MD) of TSS at 1 week: MD, \u20130.32 (\u20130.52, \u20130.12); at 2 weeks: MD, \u20130.25 (\u20130.35, \u20130.14); at 4 weeks: MD, \u20134.07 (\u20134.71, \u20133.43); at 8 weeks: MD, \u20134.22 (\u20134.73, \u20133.72); at 12 weeks: MD, \u20135.63 (\u20136.14, \u20135.13); all\n                      <jats:italic>P<\/jats:italic>\n                      -values were less than 0.05] and QOL [at 12 weeks: MD, \u201323.16 (\u201326.92, \u201319.39);\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001] in children with AR. It had similar efficacy compared with other antihistamines (AHs) or montelukast, without showing better control of AD severity in children. Moderate-to-low certainty evidence demonstrated that CTZ was well tolerated and did not increase the risk of severe and overall AEs, cardiotoxicity, damage to the central nervous and digestive systems, or other systems in children, except for the risk of somnolence [risk ratio, 1.62 (1.02, 2.57);\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04, compared with placebo].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Moderate-to-low certainty evidence revealed that CTZ could improve clinical improvement and QOL in children with AR and have comparable efficacy with other AHs. CTZ is well tolerated in the pediatric population, except for an increased risk of somnolence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      ], identifier [CRD42021262767].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2022.940213","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T01:45:35Z","timestamp":1661391935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Pengxiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society.","volume":"184","author":"Goncalo","year":"2021","journal-title":"Br J Dermatol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision.","volume":"140","author":"Brozek","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.anai.2018.03.028","article-title":"The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: a literature review.","volume":"121","author":"Blaiss","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection.","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12948-020-00118-5","article-title":"Cetirizine use in childhood: an update of a friendly 30-year drug.","volume":"18","author":"Parisi","year":"2020","journal-title":"Clin Mol Allergy."},{"key":"B6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4081\/mrm.2019.487","article-title":"Focus on the cetirizine use in clinical practice: a reappraisal 30 years later.","volume":"14","author":"Corsico","year":"2019","journal-title":"Multidiscip Respir Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/pds.4246","article-title":"Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.","volume":"26","author":"Motola","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11530910-000000000-00000","article-title":"Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study.","volume":"30","author":"Ferrer","year":"2010","journal-title":"Clin Drug Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14656566.2020.1830970","article-title":"The clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine.","volume":"22","author":"Nieto","year":"2021","journal-title":"Expert Opin Pharmacother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000351843","article-title":"The clinical use of cetirizine in the treatment of allergic rhinitis.","volume":"92","author":"Zhang","year":"2013","journal-title":"Pharmacology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis.","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1399-3038.2005.00351.x","article-title":"Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr.","volume":"17","author":"Chen","year":"2006","journal-title":"Pediatr Allergy Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1081-1206(10)62979-1","article-title":"Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children.","volume":"80","author":"Delgado","year":"1998","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/088318704322994958","article-title":"A comparison of cetirizine and montelukast for treating childhood perennial allergic rhinitis.","volume":"17","author":"Hsieh","year":"2004","journal-title":"Pediatr Asthma Allergy Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1398-9995.1994.tb00125.x","article-title":"Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis.","volume":"49","author":"Jobst","year":"1994","journal-title":"Allergy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1081-1206(10)62107-2","article-title":"The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.","volume":"89","author":"Lai","year":"2002","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1399-3038.2008.00816.x","article-title":"The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis.","volume":"20","author":"Lee","year":"2009","journal-title":"Pediatr Allergy Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1542\/peds.113.2.e116","article-title":"Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study.","volume":"113","author":"Ng","year":"2004","journal-title":"Pediatrics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00045391-199905000-00005","article-title":"Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis.","volume":"6","author":"Sienra-Monge","year":"1999","journal-title":"Am J Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1399-3038.1993.tb00085.x","article-title":"Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo.","volume":"4","author":"Allegra","year":"1993","journal-title":"Pediatr Allergy Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2500\/aap.2017.38.4050","article-title":"Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.","volume":"38","author":"Nayak","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/000992289703600405","article-title":"Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study.","volume":"36","author":"Pearlman","year":"1997","journal-title":"Clin Pediatr (Phila)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/pai.1996.10.9","article-title":"Treatment of seasonal allergic rhinitis in children with cetirizine or chlorpheniramine: a multicenter study.","volume":"10","author":"Tinkelman","year":"1996","journal-title":"Pediatr Asthma Allergy Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/pai.1996.10.181","article-title":"Absence of QT c prolongation with cetirizine in children aged 6 to 11 years.","volume":"10","author":"Winder","year":"1996","journal-title":"Pediatr Asthma Allergy Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/088318703322751318","article-title":"Once-daily cetirizine is safe and effective for children with allergic rhinitis with and without intermittent asthma.","volume":"16","author":"Segal","year":"2003","journal-title":"Pediatr Asthma Allergy Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/BF03259210","article-title":"Cetirizine in children with chronic allergic rhinitis: a multicentre double-blind study of two doses of cetirizine and placebo.","volume":"4","author":"Baelde","year":"1992","journal-title":"Drug Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1067\/mai.2003.1496","article-title":"Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study.","volume":"111","author":"Simons","year":"2003","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1034\/j.1399-3038.2002.01047.x","article-title":"Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months.","volume":"13","author":"Diepgen","year":"2002","journal-title":"Pediatr Allergy Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0091-6749(99)70389-1","article-title":"Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC study group. Early treatment of the atopic child.","author":"Simons","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-3038.1998.tb00356.x","article-title":"Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETA\u00a7.","volume":"9","author":"Wahn","year":"1998","journal-title":"Pediatr Allergy Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1067\/mai.2001.120015","article-title":"A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months\u2019 treatment and 18 months\u2019 posttreatment follow-up.","volume":"108","author":"Warner","year":"2001","journal-title":"J Allergy Clin Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1399-3038.1993.tb00339.x","article-title":"A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years.","author":"Masi","year":"1993","journal-title":"Pediatr Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1081-1206(10)62230-2","article-title":"Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy.","volume":"87","author":"Ciprandi","year":"2001","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1185\/03007995.2012.672405","article-title":"Safety considerations in the management of allergic diseases: focus on antihistamines.","volume":"28","author":"Yanai","year":"2012","journal-title":"Curr Med Res Opin."},{"key":"B38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: a practice parameter update.","volume":"146","author":"Dykewicz","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2165\/00003495-200464050-00008","article-title":"Cetirizine: a review of its use in allergic disorders.","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13052-019-0695-x","article-title":"Management of chronic urticaria in children: a clinical guideline.","volume":"45","author":"Caffarelli","year":"2019","journal-title":"Ital J Pediatr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s000110300050","article-title":"H1 antagonists: receptor affinity versus selectivity.","author":"Gillard","year":"2003","journal-title":"Inflamm Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/pai.13522","article-title":"Newer-generation antihistamines and the risk of adverse events in children: a systematic review.","volume":"32","author":"Miligkos","year":"2021","journal-title":"Pediatr Allergy Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1203\/00006450-200208000-00018","article-title":"Long-term evaluation of the impact of the h1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis.","volume":"52","author":"Stevenson","year":"2002","journal-title":"Pediatr Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1476-5381.2010.00907.x","article-title":"Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.","volume":"161","author":"van Ruitenbeek","year":"2010","journal-title":"Br J Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0269881107081526","article-title":"Histamine H1-receptor blockade in humans affects psychomotor performance but not memory.","volume":"22","author":"van Ruitenbeek","year":"2008","journal-title":"J Psychopharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1185\/0300799019117011","article-title":"The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.","volume":"17","author":"Hindmarch","year":"2001","journal-title":"Curr Med Res Opin."},{"key":"B47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14740338.2021.1846717","article-title":"Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.","volume":"20","author":"Ali","year":"2021","journal-title":"Expert Opin Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0119551","DOI":"10.1371\/journal.pone.0119551","article-title":"Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe.","volume":"10","author":"Poluzzi","year":"2015","journal-title":"PLoS One."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.2165\/9884960-000000000-00000","article-title":"Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.","volume":"69","author":"Phan","year":"2009","journal-title":"Drugs."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/cea.13500","article-title":"Cardiac safety of second-generation H1 -antihistamines when updosed in chronic spontaneous urticaria.","volume":"49","author":"Cataldi","year":"2019","journal-title":"Clin Exp Allergy."},{"key":"B51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2222.2007.02678.x","article-title":"BSACI guidelines for the management of chronic urticaria and angio-oedema.","volume":"37","author":"Powell","year":"2007","journal-title":"Clin Exp Allergy."},{"key":"B52","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria.","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy."},{"key":"B53","first-page":"141","article-title":"Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?","volume":"23","author":"Sanchez-Borges","year":"2013","journal-title":"J Investig Allergol Clin Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2230.2006.02278.x","article-title":"Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses.","volume":"32","author":"Asero","year":"2007","journal-title":"Clin Exp Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12325-021-01999-x","article-title":"The role of cetirizine in the changing landscape of IV antihistamines: a narrative review.","volume":"39","author":"Blaiss","year":"2022","journal-title":"Adv Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","article-title":"The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets.","volume":"9","author":"Thangam","year":"2018","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/164_2016_85","article-title":"Allergy, histamine and antihistamines.","volume":"241","author":"Church","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.940213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T01:45:41Z","timestamp":1661391941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.940213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":58,"alternative-id":["10.3389\/fped.2022.940213"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.940213","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"940213"}}